J

JAMA Network

Threads
@jamanetwork

268.5K

Followers

222

Following

2,131

Posts

N/A

Reels

1

Highlights

7/5

Photos/Videos in last 12

Bio

Home of JAMA, JAMA Network Open, JAMA Health Forum, and 10 specialty journals publishing the latest information shaping clinical medicine.

-

Avg likes

-

Avg comments

-

Engagement

0.5/wk

Posting

Likes and comments are still being collected for this account. Check back shortly.

Recent posts

Amyotrophic lateral sclerosis (#ALS) is a neurodegenerative disease characterized by progressive weakness due to degeneration of upper motor neurons in the brain and lower motor neurons in the brainstem and spinal cord. No curative therapies exist. Two oral medications, riluzole and edaravone, are approved by the FDA and modestly decrease disease progression in sporadic ALS. Tofersen, an intrathecally administered gene-based therapy, is also FDA approved and slows disease progression in patients with SOD1 pathogenic gene variants. This JAMA Review summarizes current evidence regarding the diagnosis and treatment of ALS. ๐Ÿ”— Access the full article via our link in bio. 11 May 2026 #LowBackPain is defined as pain located below the costal margin and above the inferior gluteal folds, with or without leg pain and is the leading cause of years lived with #disability worldwide, affecting people of all ages. Approximately 1 in 4 US workers report low back pain, with mean lifetime prevalence of approximately 40% in adults. Approximately 90% of cases presenting in clinical settings are classified as nonspecific low back pain, with no identified pathoanatomical cause. Initial management emphasizes advice, education, and continued activity. For acute nonspecific low back pain, first-line therapies include nonpharmacological treatments such as heat application, #spinal manipulation, massage, and #acupuncture, along with nonsteroidal anti-inflammatory drugs (#NSAIDs) and skeletal #muscle relaxants. Chronic nonspecific low back pain is less likely to resolve but is managed with exercise, psychological therapies (such as cognitive behavioral therapy), and multidisciplinary approaches, with NSAIDs considered as second-line therapy. ๐Ÿ“ Learn more about the epidemiology, pathophysiology, clinical evaluation, prognosis, and treatment of nonspecific low back pain in this JAMA Review. ๐Ÿ”— Find the full JAMA article via our link in bio. 15 Jun 2026 Alcohol-related liver disease is the leading cause of #liver-related #mortality and the most common indication for liver #transplant in Europe and the US, with mortality rates rising over the past two decades. ALD develops with chronic daily #alcohol consumption (>20 g/d for women, >30 g/d for men) and encompasses reversible #steatosis, #steatohepatitis, #fibrosis, #cirrhosis, and #hepatocellular #carcinoma. Most patients are asymptomatic or experience nonspecific symptoms; disease progression is influenced by age, sex, metabolic risk factors, viral hepatitis, smoking, and genetics. Noninvasive fibrosis tests aid early diagnosis and risk stratification. Alcohol cessation remains the primary treatment goal, with behavioral and pharmacologic therapies supported by guideline recommendations. Severe alcohol-associated hepatitis or decompensated cirrhosis warrants consideration for liver transplant. Read the full JAMA Review via our link in bio. 06 Jul 2026 A study in JAMA of more than 5 million US births indicates that more infants are not receiving intramuscular #VitaminK at birth, despite its routine use to prevent vitamin K deficiency bleeding. Nonreceipt of intramuscular #VitaminK at birth increased from about 3% in 2017 to nearly 7% in 2025. The study found higher risks of bleeding, intracranial (within the brain or skull) bleeding, and death with a bleeding diagnosis among infants who did not receive vitamin K, consistent with findings from a separate study in Sweden published in JAMA Pediatrics. These data support the public health importance of maintaining vitamin K prophylaxis at birth. ๐Ÿ“Œ Link in bio to learn more. 10 Nov 2026 A new study in JAMA highlights an often-overlooked part of ED boarding: the delay between hospital admission and when the inpatient team actually begins managing care. Researchers found that more than 17% of patients waited at least 4 hours after admission before inpatient management began, suggesting that traditional boarding metrics may not capture the full transition from the emergency department to inpatient care. ๐Ÿ“Œ Link in bio to read more. 10 Nov 2026 JAMA+ Trials brings together research, commentary, and educational content designed to help readers interpret and communicate trial evidence. Featured resources include: ๐Ÿ“Œ Theme of the Month ๐Ÿ† Editor's Choice: Clinical Trials of the Year ๐Ÿ” Search & Browse Clinical Trials ๐Ÿ“Š Guide to Statistics & Methods for Trials โš•๏ธ Integrating Clinical Trials and Practice ๐Ÿ“‹ SPIRIT and CONSORT Guideline Updates ๐Ÿ”— Explore the latest research and educational resources available through JAMA+ Trials via our link in bio. 09 Nov 2026 ๐Ÿ“Š Last month's JAMA+ Trials poll asked: "Extension studies to clinical trials..." Nearly half of respondents (46.4%) said extension studies provide valuable insight into longer-term safety and treatment durability, while 36.9% said they should be considered cohort studies rather than trials in themselves. ๐Ÿ”— Explore more discussions, polls, and perspectives on clinical trials via our link in bio. 09 Nov 2026 As #AI becomes increasingly central to #medicine and #health care, JAMA AI will provide a dedicated home for research evaluating not only what AI can do, but how it performs in #clinical care and real-world settings. Open for manuscript submissions in early 2027. ๐Ÿ“ฉ Learn more and sign up for updates via our link in bio. 09 Nov 2026 Introducing JAMA AI, a new peer-reviewed, online-only journal from the JAMA Network focused on #AI and #health #technology. Led by inaugural Editor in Chief Roy Perlis, MD, MSc, JAMA AI will publish original research and opinion spanning foundational AI and #digital health #research, #clinical translation, real-world implementation, health system transformation, global health, #MedEd, #regulation, #ethics, and #policy. ๐Ÿ“ฉ Sign up to receive updates about JAMA AI via our link in bio. 09 Nov 2026 Among adults with moderate to severe #ObstructiveSleepApnea and #obesity or overweight, once-daily oral orforglipron improved the apnea-hypopnea index at 52 weeks vs placebo in 2 randomized clinical trials. Benefit was observed in patients not receiving positive airway pressure treatment and in those receiving positive airway pressure treatment. Read the full article via our link in bio. #ScientificSessions26 09 Nov 2026 From foundational advances to real-world clinical implications, #AI is reshaping medicine. Follow JAMA AI for peer-reviewed research, expert perspectives, and discussions on the technologies transforming health care. ๐Ÿ”— Learn more about JAMA AI via our link in bio. 09 Nov 2026 A study in JAMA Neurology suggests #AI may help clinicians screen for cognitive impairment by listening to primary care visit conversations. Researchers found that machine learning models analyzing recordings of visits with patients 55 years or older with no history of memory complaints showed high accuracy in identifying #CognitiveImpairment. #Neurology ๐Ÿ“Œ Link in bio to learn more. 09 Nov 2026

Follower tracking

We have started recording @jamanetwork, but only 1 observation so far โ€” not enough to show a trend yet. Track it daily →

Download @jamanetwork's data

Everything below is derived from this account, priced on the counts shown. Delivered as CSV by emailed link.

Every post & reel

2,131 posts & reels

$21.31

Caption, likes, comments, views, duration, mentions, co-authors and sponsored status for every post and reel.

See a sample
shortcodecaptionlikescomments
DYNWhhwCbxvAmyotrophic lateral sclerosis (#ALS) is a neurodโ€ฆ
DZnnXFWH0G2#LowBackPain is defined as pain located below thโ€ฆ
DadQu4toL1YAlcohol-related liver disease is the leading cauโ€ฆ

Real rows from this account. The file continues in the same shape.

Everyone who follows them

up to 50,000 followers of 268,513 total

$250.00

Handle, full name, ID, and verified/private flags for each follower.

See the columns
usernamefull_nameuser_idis_verifiedis_privateprofile_pic_url

These are the columns. We can't show live rows: Instagram serves no follower or following list to a logged-out client, so we hold none until you order.

Everyone they follow

up to 222 accounts

$9.99

minimum

Every account this one follows, same fields.

See the columns
usernamefull_nameuser_idis_verifiedis_privateprofile_pic_url

These are the columns. We can't show live rows: Instagram serves no follower or following list to a logged-out client, so we hold none until you order.

You only pay for rows we deliver. Counts are the maximum available today; if an export comes back smaller, the difference is refunded automatically. Counts as last collected 4ย days, 21ย hours ago.

Tracking

A monthly plan, not a download: we keep reading @jamanetwork and email you what changed.

Track @jamanetwork every day ยท up to 5 accounts

We read @jamanetwork daily from today and email you the week's follower, following and post changes, with every reading so far as a CSV. Add up to 4 more accounts on the same plan. Cancel any time.

See the columns
read_atfollowersfollowingpostsfollowers_change

These are the columns of the file. It gets one row per account for every day we read it, from the day you start.

$14.99/month